Highlights Alphamab Oncology

Equities

9966

KYG0330A1013

Market Closed - Hong Kong S.E. Other stock markets 04:08:03 2024-05-23 am EDT			5-day change	1st Jan Change
4.83 ^HKD	-1.43%		-7.47%	-27.26%

May. 02	Alphamab Oncology's 2023 Loss Narrows as Revenue Rises	MT
Apr. 10	Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alphamab Oncology's 2023 Loss Narrows as Revenue Rises	May. 02	MT
Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting	Apr. 09	MT
Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr	Apr. 09	CI
Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting	Apr. 09	CI
Alphamab Oncology Unit Renews Service Provision Contract, Annual Limits	Apr. 04	MT
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. and Suzhou Alphamab Co., Ltd. Announces Renewal of the Lease Agreement	Mar. 28	CI
Alphamab Oncology Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033	Mar. 25	CI
Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine	Mar. 22	CI
Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications	Feb. 06	CI
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035	Jan. 24	CI
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	Jan. 24	MT
Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor	Dec. 07	CI
Amoytop Biotech Signs Exclusive License Deal for Liver Disease Drug With Alphamab Unit	Dec. 07	MT
Alphamab Oncology Announces First Patient Dosed in Phase Iii Study of Jskn003 for the Treatment of Advanced Her2-Low Breast Cancer	Dec. 04	CI
Alphamab Oncology Announces Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of Her2-Expressing Advanced Solid Tumors	Nov. 15	CI
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE	Nov. 06	CI
Alphamab Oncology Announces Results of Two Studies of HER2 Bispecific Antibody KN026 At the European Society of Medical Oncology	23-10-23	CI
Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO	23-10-23	CI
Alphamab Oncology's H1 Loss Narrows on Surge in Revenue	23-08-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alphamab Oncology

Equities

9966

KYG0330A1013

Highlights

Filters